- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Patricia Danzon: Cost-Effectiveness Thresholds Create Incentive to Develop Better Drugs
Cost-effectiveness thresholds can do more than just guide determinations on whether drugs have value, explained Patricia Danzon, PhD, professor at the Wharton School at the University of Pennsylvania. Using these thresholds as a requirement for reimbursement provides an incentive for research and development focused on producing new drugs that will be considered effective enough to pay for.
Cost-effectiveness thresholds can do more than just guide determinations on whether drugs have value, explained Patricia Danzon, PhD, professor at the Wharton School at the University of Pennsylvania. Using these thresholds as a requirement for reimbursement provides an incentive for research and development (R&D) focused on producing new drugs that will be considered effective enough to pay for.
Transcript (slightly modified)
How can attempts to be mindful of cost and budget be balanced with fostering innovation in the US?
When we set a threshold for what is considered a reasonable about to pay per QALY, and let’s say we pick $150,000 per quality-adjusted life year, that amount is picked taking into account what we as a society are willing to pay for health gain, given what we have to give up, the opportunity cost in terms of non-health activities, so whether it’s education or Social Security or other things.
Then, given that threshold, any product that can meet that threshold, we should be willing to pay for. So there is an incentive to R&D to produce drugs that produce effectiveness and cost savings such that they meet that threshold. If we base our prices on that cost-effectiveness threshold, we create an incentive to steer R&D towards the sort of products that will produce drugs that are cost-effective.
That’s the way in which, if we really do use cost-effectiveness as a way of rewarding drugs that do meet that threshold, we are creating an incentive to produce drugs that will meet the threshold and therefore will get reimbursed, whereas if products are priced either above the threshold or don’t have much in the way of efficacy and safety, then they would not be worth it, they would not be considered cost-effective, and that would not be a good investment. Hopefully, by our reimbursement strategy, we’re sending the signals to R&D on what is worth investing in.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
